Sickle Cell, Gene Therapy, and the Limits of Medical Triumph

In December 2023, the FDA approved the first two gene therapies with curative potential for sickle cell disease (SCD): Casgevy, which uses CRISPR to edit a patient’s own stem cells, and Lyfgenia, which uses a viral vector to deliver a functional gene. For a disease as painful and disabling as sickle cell disease, one might have expected a rush toward treatment. Yet unlike the rapid public embrace of GLP-1 drugs, that rush has not materialized. Last year, only 64 patients received Casgevy, and about 100 received Lyfgenia. In the United States, more than 100,000 people live with sickle cell disease.

Sickle Cell is Devastating

Sickle cell disease is caused by an inherited mutation that alters hemoglobin, the oxygen-carrying protein in red blood cells. Under stress, the altered hemoglobin can make red blood cells stiff, sticky, and crescent-shaped. These cells can block small blood vessels, depriving tissues of oxygen and triggering episodes of severe pain called vaso-occlusive crises. Over time, the disease can damage the lungs, heart, kidneys, and other organs. Many patients require regular blood transfusions and complex medication regimens, often including opioids for pain. Roughly half of Americans with sickle cell disease are covered by Medicaid, with Medicaid playing an even larger role for children.

The slow uptake is not a mystery of failed science. It is the result of a collision among extraordinary upfront costs, demanding clinical logistics, limited treatment capacity, fertility risks, and understandable caution among patients who have often been underserved by the medical system. 

The price of a one-time cure

The most visible barrier is the upfront cost of the therapeutics. Over the past two decades, drug spending has increasingly shifted from relatively easy-to-manufacture small-molecule drugs toward biologics, especially in cancer, autoimmune disease, and, more recently, metabolic disease. GLP-1 drugs are part of that broader shift. Medicare spending on biologics has grown by 89% since 2008 and accounts for 80% of Medicare spending on medications provided in physician offices. Among Medicaid recipients with SCD eligible for gene therapy, annual spending often exceeds $200,000.

Casgevy and Lyfgenia are not biologics. They are individualized cell-based gene therapies designed to be given once, with long-term or even lifelong benefit. That is precisely what makes them so difficult to pay for. Casgevy is priced at about $2.2 million and Lyfgenia at about $3.1 million, creating a massive upfront cost rather than a cost spread gradually over years of treatment. Private insurers and state Medicaid programs may eventually save money if the therapies prevent decades of complications, hospitalizations, and transfusions. But the bill arrives all at once.

CMS has tried to address this problem through the Cell and Gene Therapy Access Model, a voluntary program for state Medicaid agencies and manufacturers. Under the model, CMS negotiates outcomes-based agreements with manufacturers, so payment is tied in part to whether the therapy achieves the promised patient outcomes. States that participate can then make the therapies available to eligible Medicaid patients under a more predictable payment structure. The program, begun last year, has been successful in creating a payment infrastructure in roughly 33 States, but it is too early in the program for any outcome data.

Hidden Burdens

The language of “cure” obscures what treatment actually requires. Unlike drugs that are given as injections or infusions, these therapies involve removing a patient’s own blood-forming stem cells, modifying them, and then returning them after intensive chemotherapy. After initial screening, the process unfolds in several demanding steps:

• The patient receives medication that mobilizes stem cells from the bone marrow into the bloodstream, where they can be collected. Doctors also store a backup supply of unmodified stem cells in case the modified cells cannot be used or complications arise, providing a fallback option.
• The collected cells are sent to the manufacturer. There, they are either edited with CRISPR or modified with a viral vector that introduces a new genetic instruction. The patient then waits while the individualized product is manufactured, tested, frozen, and shipped back to the treatment center.
• Before infusion, the patient undergoes “conditioning chemotherapy” to clear space in the bone marrow for the modified stem cells to grow. The process induces temporary but profound immune suppression and can carry risks such as infection, infertility, mouth sores, hair loss, and prolonged hospitalization.
• The infusion itself may be the simplest part. The difficult part comes afterward, as the patient waits for the modified cells to engraft and produce healthier blood cells. That period can require weeks in or near the hospital, with transfusions, infection prevention, pain control, and close monitoring for complications.

For patients, the promise of a one-time treatment brings months of uncertainty, risk, and disruption. Two additional hurdles are easy to miss.

The first is manufacturing. This is not an off-the-shelf therapy sitting in a pharmacy refrigerator. It is a custom product made from each patient’s own cells. Both manufacturers have indicated that manufacturing and testing can take several months. If too few stem cells are collected or the modified product does not meet quality standards, the process can be delayed before chemotherapy even begins.

The second hurdle is fertility. The chemotherapy used before infusion carries a high risk of permanent infertility. For adolescents and young adults, this often means pausing treatment to consider sperm, egg, or embryo preservation, adding emotional stress, delays, and cost. For prepubertal children, standard fertility-preservation options are available at all. 

Lyfgenia also carries a rare but serious concern: the potential risk of acute myeloid leukemia, a low-frequency, dangerous blood cancer. Deaths associated with an earlier version of the treatment contributed to a black box warning (the highest possible) and the need for long-term cancer monitoring. Although Casgevy works through a different mechanism, some clinicians, “out of an abundance of caution,” apply similar long-term monitoring.

Trust, history, and communication]

The slow rollout must be understood in the context of the sickle cell community’s long history of underinvestment and structural neglect. SCD primarily affects Black patients, and many patients and families have learned to be cautious when new promises come from institutions that have not always supported them.

That caution is not merely historical memory; it is reflected in investment. Sickle cell disease has received less research and philanthropic support than some other serious inherited diseases. One comparison found that cystic fibrosis received more federal and foundation funding than sickle cell disease, despite sickle cell disease affecting a larger US population. Both are severe inherited disorders, yet their public visibility and support have not been equal.

Recent events have also made communication about sickle cell treatment feel unstable. Voxelotor, approved in 2019, was withdrawn in 2024 after concerns emerged about an imbalance between vaso-occlusive crises and deaths. For patients who believed they were benefiting, the withdrawal caused confusion and distress, especially in the absence of a full public explanation, clear tapering guidance, or a temporary access pathway. Soon afterward, a phase III trial of another FDA-approved sickle cell therapy failed to reduce pain crises compared with placebo, undermining confidence in the earlier evidence that had supported accelerated approval.

When high-profile sickle cell treatments encounter unexpected safety or efficacy issues, patients notice. For a community already facing painful disease, complicated access, and a long history of unequal support, caution about a new therapy is not resistance to science. It is a rational response to uncertainty.

The Limits of Genetic Medicine

“For many conditions, genes and their protein products are simply not the right level of intervention… the much-vaunted notion of “personalized medicine”—where treatments are customized to the attributes of the individual—cannot rely solely on genetic information. To treat disease at its root, we have to identify the level in the hierarchy of life where that root is embedded.”

Philip Bell, How Life Works 

The promise of genetic medicine has always held a seductive simplicity: find the defective gene, correct the biological error, and the disease yields. But sickle cell gene therapy reveals the limits of that story. The genetic target may be clear, and the science may be extraordinary, yet the root of the treatment problem lies above the gene—in the systems that finance, manufacture, deliver, explain, and monitor care. As Ball points out, life does not work like a machine assembled from parts. It works more like a conversation among levels. For sickle cell disease, those levels include biology, insurance design, hospital capacity, fertility counseling, regulatory communication, and trust.

This complicates personalized medicine. The phrase has come to mean medicine tailored to an individual’s molecular or genetic profile. Yet a person’s care is embedded in a health system. The truly personalized question is not “What is the genetic susceptibility?” but “What can your healthcare system provide?” For now, the future of medicine may be less about personalized genomic customization and more about delivery. Genes are not irrelevant. They are just not always the complete answer.

This is not a failure of science. The clinical results remain extraordinary, with more than 90% of treated patients free from severe vaso-occlusive crises. It is a failure of delivery. Twenty-first-century molecular medicine has arrived in a health system still organized around older models of financing, logistics, and access. In the journey from laboratory breakthrough to bedside reality, much of the impact can be lost. Without better payment models, expanded treatment capacity, fertility-preservation support, clearer communication, and deeper trust, sickle cell gene therapy risks becoming a boutique miracle rather than a widely available cure. Welcome to the age of precision medicine: precise in the lab, but still painfully imprecise in the world.